GEN Exclusives

More »

GEN News Highlights

More »
Mar 26, 2007

BioLineRx In-Licenses Two Drug Candidates from Yeda Research and Development

  • BioLineRx signed in-license agreements to develop and commercialize two new therapeutic candidates: BL-3040, a small molecule for the treatment of estrogen-regulated malignancies and osteoporosis and BL-3050, a protein complex for the treatment of atherosclerosis.

    This marks the third and fourth in-licensing agreements signed by BioLineRx since its IPO in February 2007, bringing the total number of drugs under development by the company to 14.

    The worldwide, exclusive license agreements were signed with Yeda Research and Development, the technology transfer company of the Weizmann Institute of Science.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?